Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer : The randomized Tempo Breast study
Copyright © 2024. Published by Elsevier Ltd..
INTRODUCTION: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration may offer a better balance of efficacy and safety than standard regimens, but data from previous trials are scarce.
METHODS: In this open-label, multicenter, phase II trial, patients were randomized to oral vinorelbine administered on a metronomic (50 mg three times weekly) or weekly (60 mg/m2 in cycle 1, increasing to 80 mg/m2 if well tolerated) schedule. Treatment was continued until disease progression or intolerance. The primary endpoint was disease control rate (DCR, the proportion of patients with a best overall confirmed response of CR, PR, or stable disease lasting 6 months or more).
RESULTS: One-hundred sixty-three patients were randomized and treated. The DCR was 63.4% (95% confidence interval [CI]: 52.0-73.8) with metronomic vinorelbine and 72.8% (95% CI: 61.8-82.1) with weekly vinorelbine. Weekly vinorelbine was also associated with longer progression-free survival (5.6 vs 4.0 months) and overall survival (26.7 vs 22.3 months) than metronomic vinorelbine, but was associated with more adverse events.
CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule.
CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Breast (Edinburgh, Scotland) - 74(2024) vom: 20. März, Seite 103681 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freyer, Gilles [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.breast.2024.103681 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368677532 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368677532 | ||
| 003 | DE-627 | ||
| 005 | 20240327235844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2024.103681 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM368677532 | ||
| 035 | |a (NLM)38377732 | ||
| 035 | |a (PII)S0960-9776(24)00012-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freyer, Gilles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer |b The randomized Tempo Breast study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a INTRODUCTION: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration may offer a better balance of efficacy and safety than standard regimens, but data from previous trials are scarce | ||
| 520 | |a METHODS: In this open-label, multicenter, phase II trial, patients were randomized to oral vinorelbine administered on a metronomic (50 mg three times weekly) or weekly (60 mg/m2 in cycle 1, increasing to 80 mg/m2 if well tolerated) schedule. Treatment was continued until disease progression or intolerance. The primary endpoint was disease control rate (DCR, the proportion of patients with a best overall confirmed response of CR, PR, or stable disease lasting 6 months or more) | ||
| 520 | |a RESULTS: One-hundred sixty-three patients were randomized and treated. The DCR was 63.4% (95% confidence interval [CI]: 52.0-73.8) with metronomic vinorelbine and 72.8% (95% CI: 61.8-82.1) with weekly vinorelbine. Weekly vinorelbine was also associated with longer progression-free survival (5.6 vs 4.0 months) and overall survival (26.7 vs 22.3 months) than metronomic vinorelbine, but was associated with more adverse events | ||
| 520 | |a CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule | ||
| 520 | |a CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Administration | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Disease control rate | |
| 650 | 4 | |a HR+/HER2-advanced breast cancer | |
| 650 | 4 | |a Metronomic | |
| 650 | 4 | |a Oral | |
| 650 | 4 | |a Vinorelbine | |
| 650 | 4 | |a Weekly administration | |
| 650 | 7 | |a Vinorelbine |2 NLM | |
| 650 | 7 | |a Q6C979R91Y |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Vinblastine |2 NLM | |
| 650 | 7 | |a 5V9KLZ54CY |2 NLM | |
| 700 | 1 | |a Martinez-Jañez, Noelia |e verfasserin |4 aut | |
| 700 | 1 | |a Kukielka-Budny, Bożena |e verfasserin |4 aut | |
| 700 | 1 | |a Ulanska, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Bourgeois, Hugues |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Serafin |e verfasserin |4 aut | |
| 700 | 1 | |a Calero, Juan Bayo |e verfasserin |4 aut | |
| 700 | 1 | |a Cortesi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Pintér, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Palácová, Markéta |e verfasserin |4 aut | |
| 700 | 1 | |a Cherciu, Nelli |e verfasserin |4 aut | |
| 700 | 1 | |a Petru, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Ettl, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a de Almeida, Cécilia |e verfasserin |4 aut | |
| 700 | 1 | |a Villanova, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Raymond, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Minh, Christine Ta Thanh |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzaniga, Marina E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast (Edinburgh, Scotland) |d 1997 |g 74(2024) vom: 20. März, Seite 103681 |w (DE-627)NLM091676371 |x 1532-3080 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2024 |g day:20 |g month:03 |g pages:103681 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.breast.2024.103681 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2024 |b 20 |c 03 |h 103681 | ||